arrow
Ö

Özlem Nuray Sever

university of health sciences
H指数:10
被引数:427

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Gustave Roussy免疫评分对接受一线免疫疗法为基础的联合治疗转移性肾细胞癌的预后影响:土耳其肿瘤学组肾癌联盟(TKCC)的研究结果

2026-08-060
OA
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

尿酸盐水平在转移性肾细胞癌接受纳武利尤单抗治疗中的研究:一项土耳其肿瘤学组肾癌联盟(TKCC)研究

2025-07-030
PRE
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

吸烟对纳武利尤单抗治疗肾细胞癌结局的影响:土耳其肿瘤学组肾癌联盟的真实世界数据

2025-07-010
PRE
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

在转移性肾细胞癌中 navigat ing二线疗法:免疫检查点抑制剂与酪氨酸激酶抑制剂的比较分析:土耳其肿瘤学组肾癌联盟的研究

2025-04-240
OA
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

舒尼替尼在转移性肾细胞癌中的应用:土耳其肿瘤学组肾癌协作组中不同风险组的临床结局

2025-02-101
OAAI
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

实验室指标对乳腺癌新辅助化疗疗效和生存率的影响

2024-05-275
OAAI
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

辅助PD-1抑制剂在手术切除的III/IV期肢端黑色素瘤患者中的有效性

2024-03-112
OAAI
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
2022-10-0311
OAAI
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
2021-11-024
PRE